Standard Biotools Stock Performance

LAB Stock  USD 1.28  0.07  5.19%   
On a scale of 0 to 100, Standard Biotools holds a performance score of 5. The entity has a beta of 1.28, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. Please check Standard Biotools' jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to make a quick decision on whether Standard Biotools' existing price patterns will revert.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Standard Biotools are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Standard Biotools sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1
Acquisition by Casdin Partners Master Fund, L.p. of 225000 shares of Standard Biotools at 1.1234 subject to Rule 16b-3
11/07/2025
2
Acquisition by Casdin Partners Master Fund, L.p. of 375000 shares of Standard Biotools at 1.1889 subject to Rule 16b-3
11/12/2025
3
Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 1.2392 subject to Rule 16b-3
11/14/2025
4
AI Startup AGI, Inc In Talks To Raise Money At 500 Million Valuation
11/19/2025
5
Acquisition by Casdin Partners Master Fund, L.p. of 450000 shares of Standard Biotools at 1.3028 subject to Rule 16b-3
11/20/2025
6
Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4325 subject to Rule 16b-3
11/24/2025
7
Acquisition by Casdin Partners Master Fund, L.p. of 125000 shares of Standard Biotools at 1.4201 subject to Rule 16b-3
12/02/2025
8
EY announces rollout of new physical AI platform, opening of EY.ai Lab and EY Global Robotics and Physical AI leader appointment
12/03/2025
9
Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4468 subject to Rule 16b-3
12/04/2025
10
GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT
12/09/2025
11
Tomorrow Lab Co-Hosts An Informal Party to Rock CES at The Punk Rock Museum
12/17/2025
12
Tomorrow Lab Wins Good Design Award for SymplBrush Jr.
01/07/2026
13
Anresco NJ Labs Expands Nationwide Testing Network with New Bi-Coastal Laboratories for Amazon Readiness
01/14/2026
14
Heres Why Were Not At All Concerned With Standard BioTools Cash Burn Situation
01/29/2026
15
CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
02/04/2026
Begin Period Cash Flow52.5 M
Total Cashflows From Investing Activities363.2 M

Standard Biotools Relative Risk vs. Return Landscape

If you would invest  113.00  in Standard Biotools on November 7, 2025 and sell it today you would earn a total of  15.00  from holding Standard Biotools or generate 13.27% return on investment over 90 days. Standard Biotools is generating 0.3041% of daily returns assuming volatility of 4.5045% on return distribution over 90 days investment horizon. In other words, 40% of stocks are less volatile than Standard, and above 94% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon Standard Biotools is expected to generate 5.98 times more return on investment than the market. However, the company is 5.98 times more volatile than its market benchmark. It trades about 0.07 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.

Standard Biotools Target Price Odds to finish over Current Price

The tendency of Standard Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.28 90 days 1.28 
about 78.81
Based on a normal probability distribution, the odds of Standard Biotools to move above the current price in 90 days from now is about 78.81 (This Standard Biotools probability density function shows the probability of Standard Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.28 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Standard Biotools will likely underperform. Additionally Standard Biotools has an alpha of 0.1752, implying that it can generate a 0.18 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Standard Biotools Price Density   
       Price  

Predictive Modules for Standard Biotools

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Standard Biotools. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.061.285.75
Details
Intrinsic
Valuation
LowRealHigh
0.061.175.64
Details
Naive
Forecast
LowNextHigh
0.021.115.58
Details
3 Analysts
Consensus
LowTargetHigh
1.411.551.72
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Standard Biotools. Your research has to be compared to or analyzed against Standard Biotools' peers to derive any actionable benefits. When done correctly, Standard Biotools' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Standard Biotools.

Standard Biotools Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Standard Biotools is not an exception. The market had few large corrections towards the Standard Biotools' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Standard Biotools, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Standard Biotools within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.18
β
Beta against Dow Jones1.28
σ
Overall volatility
0.15
Ir
Information ratio 0.04

Standard Biotools Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Standard Biotools for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Standard Biotools can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Standard Biotools may become a speculative penny stock
Standard Biotools had very high historical volatility over the last 90 days
The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 81.9 M.
Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 77.0% of the company shares are owned by institutional investors
Latest headline from prnewswire.com: CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

Standard Biotools Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Standard Stock often depends not only on the future outlook of the current and potential Standard Biotools' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Standard Biotools' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding352.7 M
Cash And Short Term Investments292.9 M

Standard Biotools Fundamentals Growth

Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.

About Standard Biotools Performance

By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 189.63  196.27 
Return On Tangible Assets(0.26)(0.28)
Return On Capital Employed(0.29)(0.30)
Return On Assets(0.20)(0.21)
Return On Equity(0.34)(0.36)

Things to note about Standard Biotools performance evaluation

Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Standard Biotools may become a speculative penny stock
Standard Biotools had very high historical volatility over the last 90 days
The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 81.9 M.
Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 77.0% of the company shares are owned by institutional investors
Latest headline from prnewswire.com: CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
Evaluating Standard Biotools' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Standard Biotools' stock performance include:
  • Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
  • Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Standard Biotools' stock performance is not an exact science, and many factors can impact Standard Biotools' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Standard Stock analysis

When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Valuation
Check real value of public entities based on technical and fundamental data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Correlations
Find global opportunities by holding instruments from different markets